Literature DB >> 23931282

Thalidomide-a notorious sedative to a wonder anticancer drug.

Shuang Zhou1, Fengfei Wang, Tze-Chen Hsieh, Joseph M Wu, Erxi Wu.   

Abstract

In the past 50 years, thalidomide has undergone a remarkable metamorphosis from a notorious drug inducing birth defects into a highly effective therapy for treating leprosy and multiple myeloma. Today, most notably, thalidomide and its analogs have shown efficacy against a wide variety of diseases, including inflammation and cancer. The mechanism underlying its teratogenicity as well as its anticancer activities has been intensively studied. This review summarizes the biological effects and therapeutic uses of thalidomide and its analogs, and the underlying mechanisms of thalidomide's action with a focus on its suppression of tumor growth.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23931282      PMCID: PMC4112512          DOI: 10.2174/09298673113209990198

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  87 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  The evolution of thalidomide and its IMiD derivatives as anticancer agents.

Authors:  J Blake Bartlett; Keith Dredge; Angus G Dalgleish
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

3.  Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Georg Schett; Jurgen Wollenhaupt; Kim Papp; Rik Joos; Jude F Rodrigues; Adele R Vessey; ChiaChi Hu; Randall Stevens; Kurt L de Vlam
Journal:  Arthritis Rheum       Date:  2012-10

Review 4.  Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

Authors:  R J D'Amato; S Lentzsch; K C Anderson; M S Rogers
Journal:  Semin Oncol       Date:  2001-12       Impact factor: 4.929

5.  Thalidomide suppresses melanoma growth by activating natural killer cells in mice.

Authors:  Ai Kawamata; Daisuke Ito; Takeshi Odani; Tomohide Isobe; Masayasu Iwase; Masashi Hatori; Masao Nagumo
Journal:  Oncol Rep       Date:  2006-12       Impact factor: 3.906

6.  Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease.

Authors:  J K Hitzler; H Martinez-Valdez; D B Bergsagel; M D Minden; H A Messner
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113

7.  A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway.

Authors:  Jason M Hansen; Craig Harris
Journal:  Antioxid Redox Signal       Date:  2004-02       Impact factor: 8.401

8.  A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.

Authors:  J Blake Marriott; Ian A Clarke; Anna Czajka; Keith Dredge; Kay Childs; Hon-Wah Man; Peter Schafer; Sowmya Govinda; George W Muller; David I Stirling; Angus G Dalgleish
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

9.  Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.

Authors:  Michael A Thompson; Thomas E Witzig; Shaji Kumar; Michael M Timm; Jessica Haug; Rafael Fonseca; Philip R Greipp; John A Lust; S Vincent Rajkumar
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

10.  A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.

Authors:  Howard A Fine; Lyndon Kim; Paul S Albert; J Paul Duic; Hilary Ma; Wei Zhang; Tanyifor Tohnya; William D Figg; Cheryl Royce
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

View more
  22 in total

1.  Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts.

Authors:  Xiaoying Dong; Xin Li; Minghui Li; Ming Chen; Qian Fan; Wei Wei
Journal:  Inflammation       Date:  2017-12       Impact factor: 4.092

2.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

Review 3.  Drugs for discoid lupus erythematosus.

Authors:  Sue Jessop; David A Whitelaw; Matthew J Grainge; Prativa Jayasekera
Journal:  Cochrane Database Syst Rev       Date:  2017-05-05

4.  Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.

Authors:  Boris Decourt; Denise Drumm-Gurnee; Jeffrey Wilson; Sandra Jacobson; Christine Belden; Sherye Sirrel; Michael Ahmadi; Holly Shill; Jessica Powell; Aaron Walker; Amanda Gonzales; Mimi Macias; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 5.  Gene-environment interactions in development and disease.

Authors:  C Lovely; Mindy Rampersad; Yohaan Fernandes; Johann Eberhart
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2016-09-14       Impact factor: 5.814

6.  Inhibitory effects of thalidomide on bleomycin-induced pulmonary fibrosis in rats via regulation of thioredoxin reductase and inflammations.

Authors:  Xiaoying Dong; Xin Li; Minghui Li; Ming Chen; Qian Fan; Wei Wei
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

7.  Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.

Authors:  Haiyan Zhu; Xunlong Shi; Dianwen Ju; Hai Huang; Wei Wei; Xiaoying Dong
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

Review 8.  The Role of Cullin-RING Ligases in Striated Muscle Development, Function, and Disease.

Authors:  Jordan Blondelle; Andrea Biju; Stephan Lange
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

9.  Geotemporospatial and causal inference epidemiological analysis of US survey and overview of cannabis, cannabidiol and cannabinoid genotoxicity in relation to congenital anomalies 2001-2015.

Authors:  Albert Stuart Reece; Gary Kenneth Hulse
Journal:  BMC Pediatr       Date:  2022-01-19       Impact factor: 2.125

10.  Central neurotoxicity of immunomodulatory drugs in multiple myeloma.

Authors:  Urmeel H Patel; Muhammad A Mir; Jeffrey K Sivik; Divisha Raheja; Manoj K Pandey; Giampaolo Talamo
Journal:  Hematol Rep       Date:  2015-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.